Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 24;15(1):302.
doi: 10.1007/s12672-024-01165-z.

Advances in antitumour therapy with oncolytic herpes simplex virus combinations

Xuejiao Qi  1
Affiliations
Review

Advances in antitumour therapy with oncolytic herpes simplex virus combinations

Xuejiao Qi. Discov Oncol. .

Abstract

Oncolytic Virus (OVs) is an emerging approach to tumour immunity that allows the use of natural or genetically modified viruses to specifically infect and lyse tumour cells without damaging normal cells. Oncolytic herpes simplex virus (oHSV) is one of the more widely researched and applied OVs in the field of oncology, which can directly kill tumour cells to promote anti-tumour immune responses. oHSV is one of the few viruses with good antiviral drugs, so oHSV is also more clinically safe. In recent years, in addition to monotherapy of oHSV in tumours, more and more studies have been devoted to exploring the anti-tumour effects of oHSV in combination with other therapeutic approaches. In this article we describe the progress of oHSV combination therapy against tumours in the nervous system, digestive system, reproductive system and other systems.

Keywords: Combination therapy; Tumour; oHSV.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Feola S, et al. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther. 2022;236: 108103. 10.1016/j.pharmthera.2021.108103 - DOI - PubMed
    1. Dai MH, et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg. 2010;97(9):1385–94. 10.1002/bjs.7124 - DOI - PubMed
    1. Zeyaullah M, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res. 2012;18(4):771–81. 10.1007/s12253-012-9548-2 - DOI - PubMed
    1. Ishida J, et al. Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol. 2014;7(2):292-302.e1. 10.1016/j.tranon.2014.02.016 - DOI - PMC - PubMed
    1. Tomita Y, et al. Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogates glioma invasion via the CCN1 and AKT signaling pathways. Mol Cancer Ther. 2019;18(8):1418–29. 10.1158/1535-7163.MCT-18-0799 - DOI - PubMed